New Wave Biotech and Nurasa partner to accelerate food-tech scale-up
New Wave Biotech, a UK-based developer of AI-powered bioprocess simulation software, has announced a commercial partnership with Nurasa, the Singapore-based food innovation company owned by Temasek. The collaboration aims to help food-tech and ingredient companies move from laboratory development to commercial-scale manufacturing with reduced risk and faster timelines.
Zoe Yu Tung Law, Co-Founder and CEO of New Wave Biotech
The partnership, announced on 14 January 2026, will give companies within Nurasa’s ecosystem access to New Wave Biotech’s Bioprocess Foresight platform, which enables virtual testing of downstream processing scenarios alongside automated techno-economic analysis (TEA) and life-cycle assessment (LCA) functions.
Addressing key barriers in biomanufacturing
The collaboration targets three significant challenges facing biomanufacturing scale-up: predicting downstream process performance without costly physical experimentation, translating technical decisions into clear cost and sustainability outcomes, and converting individual ingredients into market-ready products with viable commercial pathways.
New Wave Biotech’s platform combines mechanistic models with machine learning to simulate thousands of downstream processing variations, including centrifugation, filtration and drying operations. According to the company, the software has demonstrated the ability to reduce physical experiments by up to 90% and cut unit costs by more than 50%.
Zoe Yu Tung Law, Co-Founder and CEO of New Wave Biotech, said: “Scaling biomanufacturing depends on understanding not just how a process behaves, but what that means for cost, yield and sustainability. Our platform predicts technical outcomes and contextualises them through TEA and LCA, giving teams clear, data-driven insight at every stage of development.”
Combining digital simulation with physical infrastructure
Under the agreement, Nurasa will integrate New Wave Biotech’s simulation capabilities into its existing platform of services for food innovators. In return, New Wave Biotech gains access to Nurasa’s Asia-wide network, which includes food-grade pilot facilities, application development expertise, and regulatory and market-entry partnerships.
Samson Lee, Strategic Partnerships Manager of Nurasa, said: “Singapore is strengthening its position as a hub for scalable, sustainable nutrition and biomanufacturing innovation. Integrating New Wave Biotech’s bioprocess simulation and TEA/LCA contextualisation capabilities into our platform of offerings strengthens our ability to guide both startups and corporates toward commercially viable production, not just technical validation.”
Samson Lee, Strategic Partnerships Manager of Nurasa
Supporting global market entry
The partnership is designed to support ingredient companies whether they are scaling operations within Asia or targeting global markets. By linking digital modelling tools with physical scale-up environments, the two organisations aim to strengthen commercial pathways for sustainable nutrition and biomanufactured ingredients across both Asia and Europe.
Law added: “By partnering with Nurasa, we can support both startups and established companies in progressing from lab to commercially viable manufacturing with far greater clarity and lower risk — whether they are scaling in Asia or entering global markets.”
New Wave Biotech’s hybrid AI platform achieves high accuracy with minimal datasets and continues to learn across projects, providing biotech innovators with faster routes from laboratory to market.
- For more information, visit: newwavebiotech.com
